Poxel SA (POXEL) - Net Assets
Based on the latest financial reports, Poxel SA (POXEL) has net assets worth €-61.40 Million EUR (≈ $-71.79 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.00 Million ≈ $5.85 Million USD) and total liabilities (€66.41 Million ≈ $77.63 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Poxel SA liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-61.40 Million |
| % of Total Assets | -1227.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | -319.27% |
| 10-Year Change | -254.98% |
| Growth Volatility | 1924.53 |
Poxel SA - Net Assets Trend (2010–2024)
This chart illustrates how Poxel SA's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Poxel SA for the complete picture of this company's asset base.
Annual Net Assets for Poxel SA (2010–2024)
The table below shows the annual net assets of Poxel SA from 2010 to 2024. For live valuation and market cap data, see POXEL stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-58.94 Million ≈ $-68.90 Million |
-20.09% |
| 2023-12-31 | €-49.08 Million ≈ $-57.38 Million |
-169.05% |
| 2022-12-31 | €-18.24 Million ≈ $-21.33 Million |
-322.29% |
| 2021-12-31 | €8.21 Million ≈ $9.59 Million |
-69.47% |
| 2020-12-31 | €26.88 Million ≈ $31.42 Million |
-31.33% |
| 2019-12-31 | €39.14 Million ≈ $45.76 Million |
-29.83% |
| 2018-12-31 | €55.78 Million ≈ $65.22 Million |
+188.62% |
| 2017-12-31 | €19.33 Million ≈ $22.60 Million |
-50.93% |
| 2016-12-31 | €39.39 Million ≈ $46.05 Million |
+3.57% |
| 2015-12-31 | €38.03 Million ≈ $44.46 Million |
+1592.75% |
| 2014-12-31 | €-2.55 Million ≈ $-2.98 Million |
+87.27% |
| 2013-12-31 | €-20.01 Million ≈ $-23.39 Million |
-6451.85% |
| 2012-12-31 | €315.03K ≈ $368.30K |
-95.71% |
| 2011-12-31 | €7.35 Million ≈ $8.59 Million |
-30.56% |
| 2010-12-31 | €10.58 Million ≈ $12.37 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Poxel SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9841889600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €1.07 Million | % |
| Other Comprehensive Income | €-99.18 Million | % |
| Other Components | €139.01 Million | % |
| Total Equity | €-58.94 Million | 100.00% |
Poxel SA Competitors by Market Cap
The table below lists competitors of Poxel SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Garanti Yatirim Ortakligi AS
IS:GRNYO
|
$15.57 Million |
|
Dantax
CO:DANT
|
$15.58 Million |
|
Serstech AB
ST:SERT
|
$15.60 Million |
|
ICH Co Ltd
KQ:368600
|
$15.60 Million |
|
Daesang Corp Preference Shares
KO:001685
|
$15.55 Million |
|
Laon People Inc.
KQ:300120
|
$15.55 Million |
|
Swvl Holdings Corp
NASDAQ:SWVL
|
$15.54 Million |
|
Leader Steel Holdings Bhd
KLSE:9881
|
$15.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Poxel SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -49,105,000 to -58,937,000, a change of -9,832,000.
- Net loss of 18,305,000 reduced equity.
- Other comprehensive income decreased equity by 18,259,999.
- Other factors increased equity by 26,732,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-18.30 Million | -31.06% |
| Other Comprehensive Income | €-18.26 Million | -30.98% |
| Other Changes | €26.73 Million | +45.36% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Poxel SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | €0.42 | €0.25 | x |
| 2012-12-31 | €0.02 | €0.25 | x |
| 2013-12-31 | €-1.14 | €0.25 | x |
| 2014-12-31 | €-0.14 | €0.25 | x |
| 2015-12-31 | €2.12 | €0.25 | x |
| 2016-12-31 | €1.87 | €0.25 | x |
| 2017-12-31 | €0.84 | €0.25 | x |
| 2018-12-31 | €2.25 | €0.25 | x |
| 2019-12-31 | €1.51 | €0.25 | x |
| 2020-12-31 | €0.98 | €0.25 | x |
| 2021-12-31 | €0.29 | €0.25 | x |
| 2022-12-31 | €-0.63 | €0.25 | x |
| 2023-12-31 | €-1.27 | €0.25 | x |
| 2024-12-31 | €-1.23 | €0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Poxel SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -275.84%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-217.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -117.37% | 0.00% | 0.00x | 1.38x | €-9.36 Million |
| 2012 | -2265.92% | 0.00% | 0.00x | 25.98x | €-7.17 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | €-18.45 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | €-13.83 Million |
| 2015 | -32.19% | -20521.40% | 0.00x | 1.23x | €-16.04 Million |
| 2016 | -62.16% | -34843.71% | 0.00x | 1.28x | €-28.42 Million |
| 2017 | -117.42% | -428.99% | 0.08x | 3.45x | €-24.63 Million |
| 2018 | 24.25% | 18.13% | 0.71x | 1.89x | €7.95 Million |
| 2019 | -65.77% | -96.93% | 0.37x | 1.85x | €-29.66 Million |
| 2020 | -118.52% | -468.09% | 0.10x | 2.42x | €-34.55 Million |
| 2021 | -289.57% | -177.37% | 0.24x | 6.69x | €-24.58 Million |
| 2022 | 0.00% | -4658.46% | 0.02x | 0.00x | €-29.57 Million |
| 2023 | 0.00% | -1771.33% | 0.41x | 0.00x | €-30.18 Million |
| 2024 | 0.00% | -275.84% | 0.44x | 0.00x | €-12.41 Million |
Industry Comparison
This section compares Poxel SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $32,053,695
- Average return on equity (ROE) among peers: -506.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Poxel SA (POXEL) | €-61.40 Million | -117.37% | N/A | $15.56 Million |
| Abionyx Pharma SA (ABNX) | $10.68 Million | -54.53% | 1.04x | $123.48 Million |
| Abivax SA (ABVX) | $4.67 Million | -803.57% | 14.26x | $6.97 Billion |
| Adocia (ADOC) | $6.02 Million | 0.00% | 0.61x | $107.24 Million |
| Aelis Farma SA (AELIS) | $2.38 Million | -114.51% | 1.64x | $18.95 Million |
| Biophytis S.A. (ALBPS) | $-1.13 Million | 0.00% | 0.00x | $866.09K |
| Cellectis (ALCLS) | $285.90 Million | -34.76% | 0.16x | $269.37 Million |
| Advicenne (ALDVI) | $309.00K | -4021.68% | 60.10x | $20.79 Million |
| Genoway (ALGEN) | $9.00 Million | -7.64% | 2.06x | $30.11 Million |
| Integragen (ALINT) | $3.76 Million | -27.74% | 1.44x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-1.06 Million | 0.00% | 0.00x | $1.80 Million |
About Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more